

**AMENDMENT IN THE NATURE OF A SUBSTITUTE
TO H.R. 9598
OFFERED BY MR. COMER OF KENTUCKY**

Strike all after the enacting clause and insert the following:

1 SECTION 1. SHORT TITLE.

2 This Act may be cited as the “Office of National
3 Drug Control Policy Reauthorization Act”.

**4 SEC. 2. OFFICE OF NATIONAL DRUG CONTROL POLICY RE-
5 AUTHORIZATION.**

6 (a) AMENDMENTS TO THE OFFICE OF NATIONAL
7 DRUG CONTROL POLICY ACT OF 1998.—The Office of
8 National Drug Control Policy Reauthorization Act of 1998
9 (21 U.S.C. 1701 et seq.) is amended—

10 (1) in section 702 (21 U.S.C. 1701)—

11 (A) in paragraph (2)(A)(ii), by striking
12 “Government Reform” and inserting “Account-
13 ability”;

14 (B) in paragraph (3)—

15 (i) in subparagraph (L), by striking “;
16 and” and inserting a semicolon;

1 (ii) in subparagraph (M), by striking
2 the period at the end and inserting “;
3 and”; and

4 (iii) by adding at the end the fol-
5 lowing:

6 “(N) tertiary prevention support or serv-
7 ices, including opioid antagonists or overdose
8 reversal agents such as naloxone, and other
9 harm reduction activities such as overdose and
10 drug detection testing.”;

11 (C) by amending paragraph (7) to read as
12 follows;;

13 “(7) EMERGING DRUG THREAT.—The term
14 ‘emerging drug threat’ means the occurrence of a
15 new and growing trend in the illicit use or misuse
16 of a drug, class of drugs, or non-controlled sub-
17 stance, or a new or evolving method of drug con-
18 sumption or trafficking, including rapid expansion in
19 the supply of or demand for such a drug or sub-
20 stance.”.

21 (D) in paragraph (9), by striking “drug
22 laws” and inserting the following: “drug, trade,
23 and illicit drug trafficking laws”;

1 (E) in paragraph (10), by inserting after
2 “demand reduction,” the following: “illicit drug
3 trafficking,”;

4 (F) by redesignating paragraphs (15),
5 (16), and (17) as paragraphs (17), (18), and
6 (19), respectively;

7 (G) by inserting after paragraph (14) the
8 following new paragraph:

9 “(15) PRECURSOR CHEMICAL.—

10 “(A) IN GENERAL.—The term ‘precursor
11 chemical’ includes a listed chemical and an un-
12 regulated precursor.

13 “(B) LISTED CHEMICAL.—The term ‘listed
14 chemical’ has the meaning given that term in
15 section 102 of the Controlled Substances Act
16 (21 U.S.C. 802).

17 “(C) UNREGULATED PRECURSOR.—The
18 term ‘unregulated precursor’—

19 “(i) means any chemical used in the
20 production of illicit drugs that has not
21 been identified as a listed chemical under
22 the Controlled Substances Act; and

23 “(ii) does not include a solvent or rea-
24 gent.

1 “(16) STATE.—The term ‘State’ means each of
2 the several States of the United States, the District
3 of Columbia, and each territory or possession of the
4 United States.”;

5 (H) in paragraph (19), as so redesign-
6 nated—

7 (i) by redesignating subparagraphs
8 (G) and (H) as subparagraphs (H) and
9 (I), respectively; and

10 (ii) by inserting after subparagraph
11 (F) the following:

12 “(G) activities to map, track, dismantle,
13 and disrupt the financial enablers of drug traf-
14 ficking organizations, transnational criminal or-
15 ganizations, and money launderers involved in
16 the manufacture and trafficking of drugs in the
17 United States and in foreign countries;”;

18 (I) by inserting at the end the following:

19 “(20) UNITED STATES.—The term ‘United
20 States’, when used in a geographical sense, means
21 all of the States, the District of Columbia, and the
22 territories and possessions of the United States, and
23 any waters within the jurisdiction of the United
24 States.

1 “(21) EVIDENCE.—The term ‘evidence’ has the
2 meaning given that term in section 3561 of title 44,
3 United States Code.”;”;

4 (2) in section 703(d) (21 U.S.C. 1702(d))—

5 (A) in paragraph (5)(B), by striking “ac-
6 cepted by a contractor to be used in its per-
7 formance of a contract for the Office” and in-
8 serting the following: “accepted—

9 “(i) by a contractor (or subcontractor
10 thereof at any tier) for use in its perform-
11 ance of a contract for the Office; or

12 “(ii) by a grant recipient (or sub-
13 grantee thereof at any tier) for use in car-
14 rying out an award related to a fund ad-
15 ministered by the Office.”; and

16 (B) in paragraph (6), by inserting after
17 “paragraph (5)” the following: “and the reg-
18 istry shall be sent to the appropriate Congres-
19 sional committees”;

20 (3) in section 704 (21 U.S.C. 1703)—

21 (A) in subsection (a)(1)(C), by striking
22 “shall” and inserting “may”;

23 (B) in subsection (b)—

24 (i) in paragraph (16), by inserting
25 after “to treat addiction” the following: “,

1 encourage primary substance use preven-
2 tion, and increase accessibility and effec-
3 tiveness of life-saving opioid antagonists or
4 reversal agents, such as naloxone”;

5 (ii) by striking paragraph (20);

6 (iii) by redesignating paragraph (21)
7 as paragraph (20);

8 (iv) in paragraph (20), as so redesign-
9 nated, by striking the period at the end
10 and inserting “; and”; and

11 (v) by inserting at the end the fol-
12 lowing:

13 “(21) shall coordinate with the Secretary of
14 Homeland Security, the Attorney General, and the
15 Secretary of State to regarding the status of the en-
16 forcement of clauses (i) and (ii) of subparagraph (A)
17 and subparagraph (B) of section 237(a)(2) (8
18 U.S.C. 1227(a)(2)) and subparagraphs (A) and (C)
19 of section 212(a)(2) (8 U.S.C. 1182(a)(2) for the
20 purposes of ensuring such drug control and illicit
21 drug trafficking enforcement activities are ade-
22 quately resourced.”;

23 (C) in subsection (c)—

24 (i) in paragraph (1)(C), by striking
25 “supply reduction, and State, local, and

1 tribal affairs, including any drug law en-
2 forcement activities” and inserting the fol-
3 lowing: “supply reduction, accessibility to
4 life-saving opioid antagonists or reversal
5 agents, such as naloxone, and State, local,
6 and Tribal affairs, including any drug re-
7 lated law enforcement activities”;

8 (ii) in paragraph (3)(C)—

9 (I) in clause (ii), by inserting
10 after “United States” the following: “,
11 including at and between the ports of
12 entry,”;

13 (II) in clause (iii), by striking “;
14 and” and inserting a semicolon;

15 (III) in clause (iv), by striking
16 the period at the end and inserting “;
17 and”;

18 (IV) by inserting at the end the
19 following new clause:

20 “(v) requests funding for activities
21 that facilitate illicit drug use, but not in-
22 cluding overdose reversal medications, drug
23 checking, or testing technology.”;

24 (D) in subsection (d)(8)(F)(ii), by striking
25 “and at United States ports of entry by officers

1 and employees of National Drug Control Pro-
2 gram agencies and domestic and foreign law en-
3 forcement officers” and inserting the following:
4 “and at and between United States ports of
5 entry by officers and employees of National
6 Drug Control Program agencies and domestic
7 and foreign law enforcement officers”;

8 (E) in subsection (i)—

9 (i) in paragraph (1)(A), by striking
10 “to address illicit drug use issues” and in-
11 sserting the following: “to address illicit
12 drug use, prevention and treatment of
13 overdose and addiction, and law enforce-
14 ment activities”; and

15 (ii) in paragraph (2), by striking
16 “2023” and inserting “2031”; and

17 (F) in subsection (k)—

18 (i) in the heading, by striking “HARM
19 REDUCTION PROGRAMS” and inserting
20 “SUBSTANCE USE PREVENTION, HARM
21 REDUCTION, AND LIFE-SAVING TREAT-
22 MENT PROGRAMS”; and

23 (ii) in the first sentence, by inserting
24 after “drug addiction and use” the fol-
25 lowing: “with the primary goal being the

1 prevention of initial or continued use and
2 the fostering of life-saving opioid antago-
3 nists or reversal agents, such as naloxone”;

4 (4) in section 705 (21 U.S.C. 1704)—

5 (A) in subsection (a)(3)—

6 (i) in subparagraph (A), by inserting
7 after “Federal Government” the following:
8 “and such lands owned by a foreign prin-
9 cipal (as such term is defined in section
10 1(b) of the Foreign Agents Registration
11 Act of 1938 (22 U.S.C. 611)”;

12 (ii) in subparagraph (B)—

13 (I) by inserting after “the pre-
14 ceding year” the following: “, along
15 with historical comparisons over the
16 prior 20 years,”;

17 (II) in clause (i)—

18 (aa) by inserting after “seiz-
19 ing drugs,” the following: “in-
20 cluding precursor chemicals,”;
21 and

22 (bb) by striking “; and” and
23 inserting a semicolon;

1 (III) in clause (ii), by striking
2 the period at the end and inserting “;
3 and’” and

4 (IV) by inserting at the end the
5 following new clause:

6 “(iii) the effects of trends of encoun-
7 ters of inadmissible aliens at and between
8 the ports of entry, and the effect of any in-
9 creases or changes in the level of trade and
10 travel, on the capacity and ability of the
11 Department of Homeland Security compo-
12 nents to interdict and prevent the unlawful
13 entry of illicit drugs into the United States
14 by any means.”; and

15 (iii) in subparagraph (D)—

16 (I) by inserting after “the pre-
17 ceding year” the following: “, along
18 with historical comparisons over the
19 prior 20 years,”; and

20 (II) in clause (iii), by inserting
21 after “seizing drugs,” the following:
22 “including precursor chemicals,”;

23 (B) in subsection (e)(2), by inserting be-
24 fore the period at the end the following: “and

1 \$3,000,000 for each of fiscal years 2025
2 through 2031”; and

3 (C) in subsection (f)—

4 (i) in paragraph (2), by inserting after
5 “agency shall” the following: “, in accord-
6 ance with guidelines issued by the Director
7 for standard definitions, identification, and
8 review procedures,”; and

9 (ii) by striking paragraph (4);

10 (5) in section 706 (21 U.S.C. 1705)—

11 (A) in subsection (c)—

12 (i) in paragraph (1)—

13 (I) by striking subparagraph (D);

14 (II) in subparagraph (H)—

15 (aa) by inserting after
16 “identifying existing” the fol-
17 lowing: “evidence,”; and

18 (bb) by striking “will obtain
19 such data” and inserting “will
20 ensure such data is obtained”;

21 (III) in subparagraph (J)(ii), by
22 inserting “evidence,” before “data”;

23 (IV) in subparagraph (L), by in-
24 serting “evidence” after “Such other”;

25 and

1 (V) in subparagraph (M)(iv), by
2 inserting “storing and retrieving,”
3 after “collecting,”;

4 (ii) in paragraph (2)—

5 (I) by redesignating subpara-
6 graphs (E) and (F) as subparagraphs
7 (G) and (H), respectively; and

8 (II) by inserting after subpara-
9 graph (D) the following new subpara-
10 graphs:

11 “(E) The Administrator of the Office of
12 Information and Regulatory Affairs.

13 “(F) The Chief Data Officers Council.”;

14 (iii) in paragraph (3)—

15 (I) in subparagraph (B)(ii)—

16 (aa) in subclause (I), by
17 striking “; and”;

18 (bb) in subclause (II), by
19 striking the period at the end
20 and inserting “; and”; and

21 (cc) by inserting at the end
22 the following new subclause:

23 “(III) an analysis of the effects
24 of trends of encounters of inadmis-
25 sible aliens at and between the ports

1 of entry, and the effect of any in-
2 creases or changes in the level of
3 trade and travel, on the capacity and
4 ability of the Department of Home-
5 land Security to interdict and prevent
6 the unlawful entry of illicit drugs into
7 the United States by any means.”;
8 and

9 (II) by adding at the end the fol-
10 lowing new subparagraph:

11 “(D) REQUIREMENT FOR CARIBBEAN BOR-
12 DER COUNTERNARCOTICS STRATEGY.—

13 “(i) PURPOSES.—The Caribbean Bor-
14 der Counternarcotics Strategy shall—

15 “(I) set forth the strategy of the
16 Federal Government for preventing
17 the illegal trafficking of drugs through
18 the Caribbean region into the United
19 States, including through ports of
20 entry, between ports of entry, and
21 across air and maritime approaches;

22 “(II) state the specific roles and
23 responsibilities of each relevant Na-
24 tional Drug Control Program agency
25 for implementing the strategy;

1 “(III) identify the specific re-
2 sources required to enable the relevant
3 National Drug Control Program agen-
4 cies to implement the strategy, to the
5 extent practicable; and

6 “(IV) be designed to promote,
7 and not hinder, legitimate trade and
8 travel.

9 “(ii) SPECIFIC CONTENT RELATED TO
10 PUERTO RICO AND THE UNITED STATES
11 VIRGIN ISLANDS.—The Caribbean Border
12 Counternarcotics Strategy shall include—

13 “(I) a strategy to prevent the il-
14 legal trafficking of drugs to or
15 through Puerto Rico and the United
16 States Virgin Islands, including meas-
17 ures to substantially reduce drug-re-
18 lated violent crime on such islands;
19 and

20 “(II) recommendations for addi-
21 tional assistance or authorities, if any,
22 needed by Federal, State, and local
23 law enforcement agencies relating to
24 the strategy, including an evaluation
25 of Federal technical and financial as-

1 sistance, infrastructure capacity build-
2 ing, and interoperability deficiencies.”;
3 and

4 (iv) in paragraph (5), by striking
5 “data” each place it appears and inserting
6 “evidence, data,”;

7 (B) in subsection (f)—

8 (i) in paragraph (1), by striking “pub-
9 licly available in a machine-readable for-
10 mat” and inserting the following: “publicly
11 available as an open Government data
12 asset (as such term is defined in section
13 3502 of title 44, United States Code)”;

14 (ii) in paragraph (2), by inserting
15 after “searchable format” the following:
16 “available for bulk download to the extent
17 practicable”; and

18 (iii) by amending paragraph (3) to
19 read as follows:

20 “(3) DATA.—The data included in the Drug
21 Control Data Dashboard shall be updated annually
22 with final data, and to the extent practicable, up-
23 dated quarterly with provisional data, that aligns
24 with the goals of the performance measurement sys-

1 tem required under subsection (h) and include, at a
2 minimum, the following:

3 “(A) For each substance identified by the
4 Director as having a significant impact on illicit
5 drug use in the United States, data sufficient
6 to—

7 “(i) assess supply reduction efforts,
8 including, to the extent practicable, the
9 total amount of substances seized;

10 “(ii) assess drug use behaviors;

11 “(iii) estimate the prevalence of sub-
12 stance use disorders;

13 “(iv) show the number of fatal and
14 non-fatal overdoses; and

15 “(v) assess the provision of substance
16 use disorder treatment.

17 “(B) Any quantifiable measures the Direc-
18 tor determines to be appropriate to detail
19 progress toward the achievement of the goals of
20 the National Drug Control Strategy, including,
21 to the extent practicable, data disaggregated by
22 specific geographic areas or sub-populations of
23 interest.

24 “(C) Data sufficient to assess the effective-
25 ness of such substance use disorder treatments.

1 “(D) To the extent practicable, data suffi-
2 cient to show the extent of prescription drug di-
3 version, trafficking, and misuse in the calendar
4 year and each of the previous 3 calendar years.

5 “(E) Any quantifiable measures the Direc-
6 tor determines to be appropriate to detail
7 progress toward the achievement of the goals of
8 the National Drug Control Strategy, including
9 to the extent practicable, data disaggregated by
10 specific geographic areas or sub-populations of
11 interest.”; and

12 (C) in subsection (g)(2)—

13 (i) in subparagraph (D), by striking
14 “narcotics” and inserting “drugs”;

15 (ii) in subparagraph (E), by striking
16 “drug use” and inserting “illegal drug
17 use”; and

18 (iii) in subparagraph (F), by striking
19 “drug use” and inserting “illegal drug
20 use”;

21 (6) in section 707 (21 U.S.C. 1706)—

22 (A) in subsection (l)(2)(F), by inserting
23 “and authorities enforcing illicit drug traf-
24 ficking laws” after “task forces”;

1 (B) in subsection (m)(2), by inserting “,
2 authorities enforcing illicit drug trafficking
3 laws,” after “agencies”;

4 (C) in subsection (p)—

5 (i) in paragraph (5), by striking “;
6 and” and inserting a semicolon;

7 (ii) in paragraph (6), by striking the
8 period at the end and inserting “; and”;
9 and

10 (iii) by inserting at the end the fol-
11 lowing new paragraph:

12 “(7) \$298,579,000 for each of fiscal years 2025
13 through 2031.”;

14 (D) in subsection (s)—

15 (i) in the matter before paragraph
16 (1), by striking “The Director” and insert-
17 ing “Except as provided in subsection
18 (t)(2), the Director”;

19 (ii) in paragraph (2), by striking “;
20 and” and inserting a semicolon;

21 (iii) in paragraph (3), by striking the
22 period at the end and inserting “; and”;
23 and

24 (iv) by adding at the end the fol-
25 lowing:

1 “(4) enhancing fentanyl seizure and interdiction
2 activities.”; and

3 (E) by adding at the end the following:

4 “(t) SUPPLEMENTAL GRANTS FOR FENTANYL
5 INTERDICTION ACTIVITIES.—

6 “(1) MINIMUM ALLOCATION OF FUNDS FOR
7 FENTANYL INTERDICTION ACTIVITIES.—Of the
8 amounts allocated for grants under subsection (s),
9 not less than \$5,000,000 shall be allocated for the
10 purpose of making grants under subsection (s)(4).

11 “(2) ADDITIONAL FUNDS.—In addition to
12 amounts allocated under subparagraph (A) for the
13 purpose of making grants under subsection (s)(4),
14 the Director may use amounts otherwise appro-
15 priated to carry out this section for such purpose.

16 “(u) ADDITIONAL JUDICIARY PROSECUTORIAL RE-
17 SOURCES.—

18 “(1) TEMPORARY REASSIGNMENT OF ASSIST-
19 ANT UNITED STATES ATTORNEYS.—

20 “(A) AUTHORITY.—The Attorney General
21 may identify assistant United States attorneys
22 who may be made available for temporary reas-
23 signment under subsection (b)(2) for a period
24 of time determined by the Attorney General in
25 coordination with the Director, during which an

1 assistant United States attorney shall prioritize
2 the investigation and prosecution of organiza-
3 tions and individuals trafficking in fentanyl or
4 fentanyl analogues.

5 “(B) EXTENSION OF REASSIGNMENT.—
6 Such reassignment may be extended by the At-
7 torney General for such time as may be nec-
8 essary to conclude any ongoing investigation or
9 prosecution in which the assistant United
10 States attorney is engaged.

11 “(2) PROCESS FOR TEMPORARY REASSIGN-
12 MENT.—The Attorney General may establish a proc-
13 ess under which the Director, in consultation with
14 the Executive Boards of each designated high inten-
15 sity drug trafficking area, may request such an as-
16 sistant United States attorney to be so temporarily
17 reassigned.

18 “(v) USE OF FUNDS TO COMBAT FENTANYL TRAF-
19 FICKING.—

20 “(1) REQUIREMENT.—As part of the docu-
21 mentation that supports the President’s annual
22 budget request for the Office, the Director shall sub-
23 mit to Congress a report describing the use of
24 HIDTA funds for the purposes of enhancing
25 fentanyl seizure and interdiction activities under

1 subsection (s)(4) or (t) and to investigate and pros-
2 ecute organizations and individuals trafficking in
3 fentanyl or fentanyl analogues in the prior calendar
4 year.

5 “(2) CONTENTS.—The report shall include—

6 “(A) the amounts of fentanyl or fentanyl
7 analogues seized by HIDTA-funded initiative in
8 the area during the previous year; and

9 “(B) law enforcement intelligence and pre-
10 dictive data from the Drug Enforcement Ad-
11 ministration showing patterns and trends in
12 abuse, trafficking, and transportation in
13 fentanyl and fentanyl analogues.

14 “(w) REPORT ON DATA ANALYTICAL SERVICES PRO-
15 GRAM.—

16 “(1) REPORT.—With respect to the Data Ana-
17 lytical Services program (formally known as Hemi-
18 sphere), and any successor program, the Director
19 shall submit to the Committee on Oversight and Ac-
20 countability and the Committee on the Judiciary of
21 the House of Representatives, and the Committee on
22 the Judiciary of the Senate a report every two years
23 on any activities of the program—

24 “(A) funded by the Office; and

1 “(B) carried out in two years prior to the
2 submission of the report.

3 “(2) CONTENTS OF REPORT.—The report re-
4 quired by paragraph (1) shall include the following:

5 “(A) A documentation of any activities of
6 the Data Analytical Services program, includ-
7 ing—

8 “(i) the amount of searches conducted
9 for each HIDTA; and

10 “(ii) each requesting local law enforce-
11 ment jurisdiction.

12 “(B) Information on how the program was
13 funded and how funds were expended under the
14 program, including information on any—

15 “(i) funding sources derived from
16 each HIDTA’s funding allocation for a
17 HIDTA, or any other source of funding,
18 for the program; and

19 “(ii) payments made by the program
20 to any non-governmental entity or external
21 vendor.

22 “(C) A description of any policies and
23 guidelines provided to HIDTA personnel and
24 local law enforcement jurisdictions governing
25 the operation of the program in order to ensure

1 that such program does not infringe on rights
2 protected under the Fourth Amendment or vio-
3 late legally protected privacy of United States
4 citizens or individuals legally in the United
5 States, along with any recommendations by the
6 Director to strengthen such policies and guide-
7 lines.”;

8 (7) in section 709(f)(1) (21 U.S.C. 1708(f)(1)),
9 by striking “shall” and inserting “may”;

10 (8) in section 709 (21 U.S.C. 1708)—

11 (A) in subsection (f)(2)(B)(iii), by insert-
12 ing after “professionals” the following: “includ-
13 ing experts in evidence-based media campaigns,
14 education, and evaluation”; and

15 (B) in subsection (g), by striking “2023”
16 and inserting “2031”;

17 (9) in section 711 (21 U.S.C. 1710), including
18 the headings, by striking “Command and Control
19 Plan” each place it appears and inserting “Strategic
20 Plan”; and

21 (10) in section 714 (21 U.S.C. 1711), by insert-
22 ing before the period at the end the following: “and
23 \$20,000,000 for each of fiscal years 2025 through
24 2031”.

1 (b) AMENDMENTS TO THE ANTI-DRUG ABUSE ACT
2 OF 1988.—The Anti-Drug Abuse Act of 1988 (Public Law
3 100–690) is amended—

4 (1) in section 1024(a) (21 U.S.C. 1524(a)), by
5 inserting before the period at the end the following:
6 “and \$109,000,000 for each of fiscal years 2025
7 through 2031”; and

8 (2) in section 1032(b) (21 U.S.C. 1532(b))—

9 (A) by striking “\$125,000” each place the
10 term appears and inserting “\$150,000”; and

11 (B) in paragraph (3)—

12 (i) by striking subparagraph (A) and
13 inserting the following:

14 “(A) IN GENERAL.—Subject to subpara-
15 graph (F), the Administrator may award up to
16 2 additional grants under this paragraph to an
17 eligible coalition awarded a grant under para-
18 graph (1) or (2) for any first fiscal year after
19 the end of the 4-year or 9-year period following
20 the period of the initial or subsequent grant
21 under paragraph (1) or (2), as the case may
22 be.”;

23 (ii) in subparagraph (B), by striking
24 “a renewal grant” and inserting “up to 2
25 renewal grants”;

1 (iii) in subparagraph (C), by striking
2 “an additional grant” and inserting “the
3 additional grants”; and

4 (iv) by striking subparagraph (D) and
5 inserting the following:

6 “(D) RENEWAL GRANTS.—Subject to sub-
7 paragraph (F), the Administrator may award a
8 renewal grant to a grant recipient under this
9 paragraph for each fiscal year of the 4-fiscal-
10 year period following the first fiscal year for
11 which an additional grant under this paragraph
12 is awarded in an amount not to exceed the
13 amount of non-Federal funds raised by the coa-
14 lition, including in-kind contributions, for that
15 fiscal year.”.

16 (c) REAUTHORIZATION OF THE NATIONAL COMMU-
17 NITY ANTI-DRUG COALITION INSTITUTE.—Section 4(d)
18 of Public Law 107-82 (21 U.S.C. 1521 note) is amended
19 by striking “section 1032 of the National Narcotics Lead-
20 ership Act of 1988 (15 U.S.C. 1532), make a grant of
21 \$2 million under subsection (a), for each of the fiscal years
22 2018 through 2023” and inserting “section 1024 of the
23 National Narcotics Leadership Act of 1988 (21 U.S.C.
24 1524), make a grant of \$2,500,000 under subsection (a),
25 for each of the fiscal years 2025 through 2031”.

1 (d) REAUTHORIZATION OF COMMUNITY-BASED COA-
2 LITION ENHANCEMENT GRANTS TO ADDRESS LOCAL
3 DRUG CRISES.—Subsection (i) of section 103 of the Com-
4 prehensive Addiction and Recovery Act of 2016 (21 U.S.C.
5 1536) is amended by inserting before the period at the
6 end the following: “and \$5,200,000 for each of fiscal years
7 2025 through 2031”.

8 (e) REPORT REGARDING LIFE-SAVING OPIOID AN-
9 TAGONISTS OR REVERSAL AGENTS.—The Office of Na-
10 tional Drug Control Policy Reauthorization Act of 2006
11 (Public Law 109–469) is amended by adding at the end
12 the following new section:

13 **“SEC. 1121. REQUIREMENT FOR LIFE SAVING OPIOID OVER-**
14 **DOSE REVERSAL STUDY.**

15 “(a) FINDING.—Congress finds that it is vital to sup-
16 port access to treatment and emergency intervention tools
17 to address drug addiction while also pursuing strategies
18 to ensure communities have readily available access to life-
19 saving drug overdose reversal medications, including
20 opioid antagonists or reversal agents, such as naloxone,
21 in case of an emergency.

22 “(b) REPORT.—Not later than 180 days after the
23 date of the enactment of this section, the Director of the
24 Office of National Drug Control Policy shall submit to
25 Congress a report that contains the following:

1 “(1) A summary of the relevant roles, respon-
2 sibilities, and authorities of each relevant National
3 Drug Control Program agency to ensure that life-
4 saving drug overdose reversal medications are read-
5 ily available in case of an emergency, including life-
6 saving opioid antagonists or reversal agents, such as
7 naloxone, across the Nation.

8 “(2) A strategy for the Federal Government to
9 ensure that State, local, and Tribal governments,
10 and agencies thereof including law enforcement and
11 public health and safety entities, have life-saving
12 drug overdose reversal medications readily available
13 in case of an emergency, including life-saving opioid
14 antagonists or reversal agents, such as naloxone,
15 which at a minimum identifies—

16 “(A) any Federal and State policies and
17 actions necessary for the relevant National
18 Drug Control Program agencies to take to ad-
19 dress—

20 “(i) the challenges faced by phar-
21 macists, prescription drug providers, dis-
22 pensers (including manufacturers, distribu-
23 tors, and retailers), and other health care
24 providers, to make such medications read-

1 ily available to patients over the counter
2 for emergency use;

3 “(ii) the challenges faced by phar-
4 macists, health care providers, and State
5 health officials to educate the public on the
6 risks and benefits of such medications, in-
7 cluding how to effectively use such medica-
8 tions; and

9 “(iii) the appropriate training of State
10 and local health care providers and first
11 responders on the use of such medications;
12 and

13 “(B) identifies any budgetary resources,
14 personnel resources, licensing requirements, and
15 legal authorities that relevant National Drug
16 Control Program agencies needs to enable the
17 availability of such life-saving emergency drug
18 overdose medications;

19 “(3) A summary of policies in effect before the
20 submission of the report that are administered by—

21 “(A) the Director of the Office National
22 Drug Control Policy;

23 “(B) the Secretary of Health and Human
24 Services; and

1 “(C) each National Drug Control Program
2 agency, as applicable.

3 “(4) A summary of the specific actions taken
4 over the previous 10 years before the submission of
5 the report by the Substance Abuse and Mental
6 Health Services Administration and the Drug En-
7 forcement Administration to coordinate with one an-
8 other and with State health agencies to ensure
9 that—

10 “(A) such treatments, including medica-
11 tions, are accessible to the public; and

12 “(B) appropriate public education on the
13 use of, and the risks and benefits of, such treat-
14 ments, including medications, are readily avail-
15 able.

16 “(c) UPDATES.—Any significant update made to the
17 strategy included in the report required by paragraph
18 (2)(B) after such report is submitted shall be included in
19 the next National Drug Control Strategy submitted to
20 Congress after such update is made.”.

